Group 1 - The core revenue of the company for the first half of 2025 reached 375 million yuan, with new orders amounting to 532 million yuan, reflecting a year-on-year increase of 7.39% [1] - The total backlog of orders stood at 1.112 billion yuan, which is a 14.29% increase compared to the end of 2024 [1] - The company experienced growth across all business segments, with a combined year-on-year increase of 6.86% in new projects for IND and NDA applications [1] Group 2 - The company is a leading comprehensive R&D service provider in the biopharmaceutical non-clinical research sector, recognized for its international service capabilities [2] - As of June 30, 2025, the company has successfully assisted in over 200 innovative drug research services, including several groundbreaking therapies and products [2] - The strategic project in Nantong has been successfully implemented, covering an area of 24,000 square meters and featuring 130 international standard animal housing units, which will enhance the company's capacity and efficiency in innovative molecules and advanced therapies [2]

Core Insights - The company reported a revenue of 375 million yuan for the first half of 2025, impacted by a slowdown in investment and market demand in the domestic pharmaceutical industry, leading to increased competition and reduced sales order prices [1] - New order value reached 532 million yuan, a year-on-year increase of 7.39%, while the backlog of orders grew to 1.112 billion yuan, up 14.29% from the end of 2024 [1] - The company maintained a strong focus on R&D, with R&D expenditure as a percentage of revenue rising from 3.67% to 5.94%, reflecting a commitment to technological innovation and long-term growth potential [1] Business Performance - All business segments performed well, with the core IND and NDA new project numbers increasing by 6.86% year-on-year, showcasing the company's strong market expansion capabilities [1] - The company secured one new authorized invention patent during the reporting period, bringing the total number of authorized patents to 69 by the end of the reporting period [1] International Expansion - The company has established itself as a leading CRO in China, being one of the first to obtain GLP certifications from NMPA, OECD, and FDA, aligning with international standards [2] - Significant growth in international business new orders was noted, enhancing the company's recognition and influence in the global market [2] - The company has assisted in over 200 innovative drug research services, including several groundbreaking therapies and products, demonstrating its capability in both domestic and international markets [2] Capacity Development - The company successfully launched its strategic project in Nantong, covering an area of 24,000 square meters and planning 130 international standard animal housing units, which will enhance its capabilities in innovative molecules and advanced therapies [3]

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management, not exceeding RMB 330 million, to enhance fund efficiency while ensuring project funding needs are met [1][3]. Fundraising Situation - The company issued 35,244,904 shares at a price of RMB 19.06 per share, raising a total of RMB 671.7679 million, with a net amount of RMB 609.6449 million after deducting issuance costs [2]. Cash Management Details - The purpose of cash management is to improve the efficiency of fund usage while ensuring the safety of the raised funds and not affecting project construction [3]. - Investment products will include high-security, liquid deposit products, and the funds can be rolled over and returned to the special account upon maturity [3]. - The decision is valid for 12 months starting from October 14, 2025, with the management team authorized to make investment decisions [3]. Impact on the Company - The use of idle funds for cash management will not affect the company's normal cash flow or the operation of fundraising projects, and it aims to enhance fund efficiency and returns for shareholders [4]. Review Procedures and Opinions - The cash management plan has been approved by the board and supervisory committee, and does not require shareholder meeting approval [6]. - The supervisory committee and the sponsor believe the plan complies with regulations and will not harm the interests of the company or minority shareholders [6].

格隆汇8月28日丨益诺思(688710.SH)发布中报，2025上半年实现营业总收入3.75亿元，同比下降 38.04%；归属母公司股东净利润-1518.95万元，上年同期净利润为9563.91万元；基本每股收益为-0.11 元。 ...

证券代码：688710 证券简称：益诺思 公告编号：2025-032 上海益诺思生物技术股份有限公司 关于召开2025年第三次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开日期时间：2025 年 9 月 23 日 14 点 30 分 网络投票起止时间：自2025 年 9 月 23 日 至2025 年 9 月 23 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 股东大会召开日期：2025年9月23日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （一） 股东大会类型和届次 2025年第三次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 联网投票平台的投票时间为股东大会召开当日的 9:15- ...

证券代码：688710 证券简称：益诺思 公告编号：2025-026 上海益诺思生物技术股份有限公司 第三届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海益诺思生物技术股份有限公司（以下简称"公司"）第三届监事会第十 二次会议于2025年8月27日在公司会议室以现场结合通讯的方式召开，本次会议 应出席监事3人，实际出席会议监事3人。会议由公司监事会主席高莉女士主持。 此次会议的通知、召集、召开、表决程序符合《中华人民共和国公司法》等 法律、法规、规范性文件及《公司章程》的规定，会议决议合法有效。 二、监事会会议审议情况 1、 审议通过了《关于公司<2025年半年度报告>及摘要的议案》。 经审议，监事会同意《关于公司<2025年半年度报告>及摘要的议案》 监事会认为：公司《2025年半年度报告》的编制和审议程序符合法律、法规 和《公司章程》的规定。报告内容能从各个方面真实地反映出公司2025年半年度 的经营管理和财务状况等事项。监事会及全体监事保证公司《2025年半年 ...

Financial Performance - The company's operating revenue for the first half of 2025 was CNY 375.23 million, a decrease of CNY 230.41 million or 38.04% compared to the same period last year, primarily due to intense market competition and significant price declines in sales orders [19]. - Basic earnings per share for the first half of 2025 were CNY -0.11, down 112.22% from CNY 0.90 in the same period last year [20]. - The total profit for the reporting period was CNY 536,152.20, a decrease of 99.49% compared to the same period last year, which was CNY 104,678,154.39 [22]. - The net profit attributable to shareholders was -CNY 15,189,524.22, representing a year-on-year decline of 115.88% from CNY 95,639,106.27 [22]. - The gross profit margin of the main business decreased due to competitive pressures leading to lower order prices, indicating potential further declines in performance if market conditions do not improve [99]. - The company reported a revenue of CNY 37,522.86 million, a decrease of 38.04% year-on-year, primarily due to intensified market competition and a significant decline in sales order prices [100]. - The net profit attributable to shareholders was CNY -1,518.95 million, representing a year-on-year decline of 115.88% [100]. Research and Development - The R&D investment accounted for 5.94% of operating revenue, an increase of 2.27 percentage points compared to 3.67% in the previous year [20]. - The total R&D investment amounted to ¥22,272,917.89, representing a 0.15% increase compared to the previous year, with R&D investment as a percentage of revenue rising from 3.67% to 5.94% [83]. - The company has developed key technology platforms for toxicological biomarker evaluation and innovative drug safety evaluation systems [31]. - The company has established a non-clinical evaluation system for innovative drugs, focusing on gene therapy products, new XDC drugs, and innovative vaccines, successfully passing key project evaluations with the highest performance rating [50]. - The company has developed innovative drug evaluation methods based on organoid models in five areas, enhancing non-clinical evaluation efficiency and accuracy [51]. - The company has established a high-quality comprehensive evaluation platform for innovative drugs, enhancing its core competitiveness and expanding its service range in ophthalmic drug evaluation and inhalation formulation evaluation [77]. Market and Competitive Landscape - The domestic CRO market is expected to grow at a compound annual growth rate (CAGR) of approximately 9.9% from 2023 to 2026, reaching 1,126.5 billion yuan by 2026 [38]. - The global CRO market size is projected to exceed 147.7 billion USD by 2030, with a CAGR of 9.0% from 2023 to 2026 [38]. - The company is focusing on enhancing its competitive edge through targeted marketing strategies and professional branding to attract new clients [35]. - Recent government policies are expected to significantly support the innovative drug industry, including expedited clinical trial approval processes [40]. - The company aims to leverage the improving funding environment for innovative drug development to capture new growth opportunities as a leading non-clinical CRO [39]. Operational Efficiency - The company implemented cost-reduction and efficiency-enhancement measures to optimize its operational management system in response to market changes [43]. - Operating costs were CNY 27,008.02 million, down 29.24% year-on-year, attributed to ongoing cost reduction and efficiency improvement measures [102]. - The net cash flow from operating activities was CNY 6,639,008.62, an increase of CNY 49,850,569.30 compared to the previous year [22]. - The company is actively monitoring the volatility in the prices of key raw materials, which could adversely affect business performance if significant fluctuations occur [98]. Corporate Governance and Compliance - The company has not reported any mergers or market expansion strategies in the current financial period [121]. - The company has not made any progress on stock incentive plans or employee stock ownership plans during the reporting period [121]. - The company has committed to a profit distribution policy that will be strictly followed post-IPO, as approved in the 2022 shareholder meeting [126]. - The company has established partnerships with over 950 pharmaceutical companies and research institutions globally, creating a comprehensive customer network in the biopharmaceutical sector [71]. Shareholder Commitments and Lock-up Arrangements - The controlling shareholder, Yigong General Hospital, commits not to transfer or manage shares held before the IPO for 36 months from the listing date [130]. - If the stock price falls below the issue price for 20 consecutive trading days within 6 months post-listing, the lock-up period will automatically extend by at least 6 months [130]. - The company will implement share buyback measures if the stock price falls below the audited net asset value per share for 20 consecutive trading days [141]. - The total amount for share buybacks in a fiscal year will not exceed 20% of the audited net profit attributable to the parent company [143]. Talent and Human Resources - The number of R&D personnel increased to 894, representing 81.87% of the total workforce, up from 80.66% in the previous year [91]. - The average salary for R&D personnel decreased to RMB 9.75 million from RMB 10.14 million year-on-year [91]. - The company aims to enhance its core competitiveness by focusing on talent development, achieving a 10% annual conversion rate for reserve talents [54]. - The company faces risks related to talent retention and technological upgrades, which are critical for maintaining competitive advantage in the pharmaceutical industry [92]. Legal and Regulatory Matters - There are no significant lawsuits or arbitration matters reported during the reporting period [172]. - The company has not received any penalties or corrective actions related to legal violations during the reporting period [172]. - The commitment to avoid competition is valid as long as the company remains in operation and the controlling shareholder retains control [164].

国泰海通证券股份有限公司 | 序号 | 项目名称 | 项目总投资 | 拟投入募集资金额 | | --- | --- | --- | --- | | 1 | 益诺思总部及创新转化中心 | 104,500.00 | 47,964.49 | | | 项目 | | | | 2 | 高品质非临床创新药物综合 | 38,471.19 | 13,000.00 | | | 评价平台扩建项目 | | | | | 合计 | 142,971.19 | 60,964.49 | 关于上海益诺思生物技术股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为上 海益诺思生物技术股份有限公司（以下简称"益诺思"、"公司"或"发行人"） 首次公开发行股票并在科创板上市持续督导的保荐机构，根据《证券发行上市保 荐业务管理办法》《上市公司募集资金监管规则》《上海证券交易所科创板上市公 司自律监管规则适用指引第 1 号——规范运作》等有关法律法规和规范性文件的 要求，就益诺思使用部分暂时闲置募集资金进行现金管理的事项进行了审慎核查， 并发表如下核查意见: 一、募集资金基本情况 ...

证券代码：688710 证券简称：益诺思 公告编号：2025-027 上海益诺思生物技术股份有限公司 2025年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会出具的《关于同意上海益诺思生物技术股份有 限公司首次公开发行股票注册的批复》（证监许可〔2024〕762 号），公司首次 公开发行人民币普通股（A 股）3,524.4904 万股（以下简称"本次发行"），每股 发行价格为人民币 19.06 元，募集资金总额人民币 67,176.79 万元，主承销商国 泰海通证券股份有限公司（原海通证券股份有限公司，以下简称"保荐机构"、 "国泰海通"））于 2024 年 8 月 29 日将扣除尚未支付的保荐及承销费 4,402.35 万元后的余款 62,774.44 万元汇入募集资金专户中。扣除发行费用人民币 6,212.29 万元，募集资金净额为人民币 60,964.49 万元。上述募集资金已经立信会计师事 务 ...

证券代码：688710 证券简称：益诺思 公告编号：2025-029 上海益诺思生物技术股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、使用部分暂时闲置募集资金进行现金管理的情况 上海益诺思生物技术股份有限公司（以下简称"公司"）于2025年8月27日 召开第三届董事会第十九次会议和第三届监事会第十二次会议，审议通过了《关 于使用部分暂时闲置募集资金进行现金管理的议案》，同意公司在保证募集资金 项目资金需求的前提下，使用不超过人民币3.30亿元（含本数）的暂时闲置募集 资金进行现金管理，购买安全性高、流动性好、有保本约定的存款类产品（包括 但不限于定期存款、大额存单、七天通知存款等），且该等现金管理产品不得用 于质押，不用于以证券投资为目的的投资行为。使用期限自2025年10月14日起12 个月内有效，在前述额度及使用期限范围内，资金可以循环滚动使用。董事会授 权经营管理层行使现金管理投资决策权并签署相关法律文件，具体事项由公司财 务部负责组织实施。具体情况如下 ...